(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 21.07% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.8%.
Guardant Health's revenue in 2025 is $902,569,000.On average, 29 Wall Street analysts forecast GH's revenue for 2026 to be $159,441,977,585, with the lowest GH revenue forecast at $143,560,800,371, and the highest GH revenue forecast at $175,323,154,799. On average, 26 Wall Street analysts forecast GH's revenue for 2027 to be $203,808,440,913, with the lowest GH revenue forecast at $171,037,757,773, and the highest GH revenue forecast at $249,435,315,131.
In 2028, GH is forecast to generate $255,863,410,670 in revenue, with the lowest revenue forecast at $215,530,262,190 and the highest revenue forecast at $285,861,189,852.